David Hough, MD
- 4Articles
- 80.8KReads
- 2008–2020Active
- 33Collaborators
- 514Citations
About
David Hough, MD, has published extensively on the treatment of schizophrenia, schizoaffective disorders, and major depressive disorder, with a focus on pharmacological interventions. His work includes studies on esketamine nasal spray for rapid symptom reduction in major depressive disorder with active suicidal ideation, long-term safety assessments of esketamine combined with oral antidepressants in treatment-resistant depression, and analyses of relapse following antipsychotic discontinuation in schizophrenia. He has also contributed to research on the efficacy and tolerability of oral paliperidone extended-release tablets in acute schizophrenia.
Publications
Schizophrenia Relapse After Antipsychotic Discontinuation
June 19, 2018
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
